Analysis of Unusual Adverse Effects After Radium-223 Dichloride Administration
-
Published:2020-08-03
Issue:2
Volume:13
Page:159-163
-
ISSN:1874-4710
-
Container-title:Current Radiopharmaceuticals
-
language:en
-
Short-container-title:CRP
Author:
Frantellizzi Viviana1ORCID, Pontico Mariano2, Pani Arianna3, Pani Roberto4, De Vincentis Giuseppe5
Affiliation:
1. Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy 2. Ph.D. Program in Morphogenesis and Tissue Engineering, Sapienza University of Rome, Rome, Italy 3. Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan “Statale”, Italy 4. Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy 5. Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, Rome, Italy
Abstract
Background:
To our knowledge, no previous study or literature review has been performed
about the effects of the extravasation of therapeutic radiopharmaceutical agents and its potential consequences,
especially regarding alpha-particle emitting radiopharmaceuticals.
Methods:
Even if Radium-223 dichloride is known to be a relatively safe drug to manage, despite the
correctness of the procedures applied , unexpected delayed adverse effects can occur.
:
In our vast experience, we rarely observed lymphedema, even after some time, at the site of administration.
Results:
Management of lymphedema caused by radiopharmaceuticals administration has been addressed
through clinical examples. The sudden intervention allowed a fast remission of the signs and
symptoms complained by patients treated with Radium-223 dichloride.
Conclusions:
The management of adverse effects after radiopharmaceuticals administration as in case
of lymphedema onset, is extremely simple. These data confirm the safety of Radium-223 treatment.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Radiology, Nuclear Medicine and imaging
Reference16 articles.
1. Laroche, M.L.; Quelven,I.; Mazère,J.; Merle, L. Adverse reactions to radiopharmaceuticals in France: Analysis of the national phar-macovigilance database. Ann. Pharmacother. 2015,49(1),39-47. http://dx.doi.org/10.1177/1060028014558153 PMID: 25366341 2. Sciarra,A.; Gentilucci,A.; Salciccia,S.; Von Heland,M.; Ricciuti, G.P.; Marzio,V.; Pierella,F.; Musio,D.; Tombolini,V.; Frantel-lizzi,V.; Pasquini,M.; Maraone,A.; Guandalini,A.; Maggi, M. Psychological and functional effect of different primary treatments for prostate cancer: A comparative prospective analysis. Urol. On-col. 2018,36(7),340.e7-340.e21. http://dx.doi.org/10.1016/j.urolonc.2018.03.022 PMID: 29706458 3. Ricci,M.; Frantellizzi,V.; Bulzonetti,N.; De Vincentis, G. Re-versibility of castration resistance status after Radium-223 dichlo-ride treatment: Clinical evidence and Review of the literature. Int, J. Radiat. Biol. 2018,1-29. PMID: 30557063 4. Du,Y.; Carrio,I.; De Vincentis,G.; Fanti,S.; Ilhan,H.; Mommsen,C.; Nitzsche,E.; Sundram,F.; Vogel,W.; Oyen,W.; Lewington, V. Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. Eur, J. Nucl. Med. Mol. Imag-ing. 2017,44(10),1671-1678. http://dx.doi.org/10.1007/s00259-017-3756-7 PMID: 28631036 5. Parker,C.; Nilsson,S.; Heinrich,D.; Helle, S.I.; O’Sullivan, J.M.; Fosså, S.D.; Chodacki,A.; Wiechno,P.; Logue,J.; Seke,M.; Widmark,A.; Johannessen, D.C.; Hoskin,P.; Bottomley,D.; James, N.D.; Solberg,A.; Syndikus,I.; Kliment,J.; Wedel,S.; Boehmer,S.; Dall’Oglio,M.; Franzén,L.; Coleman,R.; Vogel-zang, N.J.; O’Bryan-Tear, C.G.; Staudacher,K.; Garcia-Vargas,J.; Shan,M.; Bruland, Ø.S.; Sartor, O. ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate can-cer, N. Engl, J. Med. 2013,369(3),213-223. http://dx.doi.org/10.1056/NEJMoa1213755 PMID: 23863050
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|